Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1984 Apr;43(2):228–231. doi: 10.1136/ard.43.2.228

Blood gold concentrations in children with juvenile rheumatoid arthritis undergoing long-term oral gold therapy.

E H Giannini, E J Brewer, D A Person
PMCID: PMC1001470  PMID: 6424588

Abstract

During an uncontrolled, open-labelled, open-ended clinical trial of auranofin in children with juvenile rheumatoid arthritis (JRA) we obtained serial blood samples for the purpose of assessing gold content. Our objectives were (1) to observe the pattern of blood gold concentrations over a period of time in children undergoing long-term oral gold therapy, and (2) to observe the effect of changing dosage levels on blood gold concentrations. The initial dosage of auranofin was 0.1 mg/kg/day with allowable increases to 0.2 mg/kg/day. A concurrent nonsteroidal anti-inflammatory drug was allowed. Twenty-one patients were enrolled in the study, and we obtained 2 or more serial samples on 13 of the children. At a constant dosage of 0.1 mg/kg/day, steady state blood gold concentrations were attained in 11 to 13 weeks of therapy and, in the absence of a dosage change, remained remarkably constant through extended periods. The blood gold concentration was related to total daily dosage rather than to the cumulative amount of gold received. Increasing or decreasing the dose resulted in a direct effect on concentration. The clinical value of blood gold levels resulting from auranofin therapy in JRA will have to be established through double-blind controlled trials.

Full text

PDF
230

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berglöf F. E., Berglöf K., Walz D. T. Auranofin: an oral chrysotherapeutic agent for the treatment of rheumatoid arthritis. J Rheumatol. 1978 Spring;5(1):68–74. [PubMed] [Google Scholar]
  2. Brewer E. J., Jr, Bass J., Baum J., Cassidy J. T., Fink C., Jacobs J., Hanson V., Levinson J. E., Schaller J., Stillman J. S. Current proposed revision of JRA Criteria. JRA Criteria Subcommittee of the Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Section of The Arthritis Foundation. Arthritis Rheum. 1977 Mar;20(2 Suppl):195–199. [PubMed] [Google Scholar]
  3. Brewer E. J., Jr, Giannini E. H. Standard methodology for Segment I, II, and III Pediatric Rheumatology Collaborative Study Group studies. I. Design. J Rheumatol. 1982 Jan-Feb;9(1):109–113. [PubMed] [Google Scholar]
  4. Gerber R. C., Paulus H. E., Bluestone R., Pearson C. M. Clinical response and serum gold levels in chrysotherapy. Lack of correlation. Ann Rheum Dis. 1972 Jul;31(4):308–310. doi: 10.1136/ard.31.4.308. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Giannini E. H., Brewer E. J., Jr, Person D. A. Auranofin in the treatment of juvenile rheumatoid arthritis. J Pediatr. 1983 Jan;102(1):138–141. doi: 10.1016/s0022-3476(83)80312-6. [DOI] [PubMed] [Google Scholar]
  6. Giannini E. H., Brewer E. J., Jr Standard methodology for Segment I, II, and III Pediatric Rheumatology Collaborative Study Group studies. II. Analysis and presentation of data. J Rheumatol. 1982 Jan-Feb;9(1):114–122. [PubMed] [Google Scholar]
  7. Gottlieb N. L. Comparative pharmacokinetics of parenteral and oral gold compounds. J Rheumatol Suppl. 1982 Jul-Aug;8:99–109. [PubMed] [Google Scholar]
  8. Harth M., Haines D. S., Bondy D. C. A simple method for the determination of gold in serum, blood, and urine by atomic absorption spectroscopy. Am J Clin Pathol. 1973 Mar;59(3):423–428. doi: 10.1093/ajcp/59.3.423. [DOI] [PubMed] [Google Scholar]
  9. Houpt J. B., Alpert B., Lotem M., Greyson N. D., Pritzker K. P., Langer F., Gross A. E. Spontaneous osteonecrosis of the medial tibial plateau. J Rheumatol. 1982 Jan-Feb;9(1):81–90. [PubMed] [Google Scholar]
  10. Kamel H., Brown D. H., Ottaway J. M., Smith W. E. Determination of gold in blood fractions by atomic-absorption spectrometry using carbon rod and carbon furnace atomisation. Analyst. 1976 Oct;101(1207):790–797. doi: 10.1039/an9760100790. [DOI] [PubMed] [Google Scholar]
  11. Kamel H., Brown D. H., Ottaway J. M., Smith W. E. Determination of gold in separate protein fractions of blood serum by carbon furnace atomic-absorption spectrometry. Analyst. 1977 Sep;102(1218):645–657. doi: 10.1039/an9770200645. [DOI] [PubMed] [Google Scholar]
  12. Levinson J. E., Balz G. P., Bondi S. Gold therapy. Arthritis Rheum. 1977 Mar;20(2 Suppl):531–535. [PubMed] [Google Scholar]
  13. Sadler P. J. The comparative evaluation of the physical and chemical properties of gold compounds. J Rheumatol Suppl. 1982 Jul-Aug;8:71–78. [PubMed] [Google Scholar]
  14. Schattenkirchner M., Kaik B., Muller-Fassbender H., Rau R., Zeidler H. Auranofin and sodium aurothiomalate in the treatment of rheumatoid arthritis. A double-blind, comparative multicenter study. J Rheumatol Suppl. 1982 Jul-Aug;8:184–189. [PubMed] [Google Scholar]
  15. Sharp J. T., Lidsky M. D., Duffy J., Thompson H. K., Jr, Person B. D., Masri A. F., Andrianakos A. A. Comparison of two dosage schedules of gold salts in the treatment of rheumatoid arthritis. Relationship of serum gold levels to therapeutic response. Arthritis Rheum. 1977 Jul-Aug;20(6):1179–1187. doi: 10.1002/art.1780200604. [DOI] [PubMed] [Google Scholar]
  16. Walz D. T., DiMartino M. J., Griswold D. E. Comparative pharmacology and biological effects of different gold compounds. J Rheumatol Suppl. 1982 Jul-Aug;8:54–60. [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES